Provided by Tiger Trade Technology Pte. Ltd.

Oragenics

0.4985
-0.0076-1.50%
Post-market: 0.4981-0.0004-0.08%17:10 EDT
Volume:22.88K
Turnover:11.51K
Market Cap:2.25M
PE:-0.14
High:0.5234
Open:0.5061
Low:0.4960
Close:0.5061
52wk High:1.45
52wk Low:0.4801
Shares:4.51M
Float Shares:4.41M
Volume Ratio:0.46
T/O Rate:0.52%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.5875
EPS(LYR):-4.5629
ROE:-1307.06%
ROA:-171.49%
PB:0.61
PE(LYR):-0.11

Loading ...

Oragenics Faces NYSE Compliance Challenges Amid Trial Progress

TIPRANKS
·
Aug 29

Oragenics Gets NYSE American Deficiency Notice over Stockholders’ Equity Shortfall

Reuters
·
Aug 29

Oragenics Reports Continued Clinical Progress, Provides Regulatory and NYSE American Listing Update

THOMSON REUTERS
·
Aug 29

Oragenics Q2 Net Loss Widens 11.3% to $2.53 Million Year over Year

Reuters
·
Aug 14

Oragenics CFO John Spencer Files Initial Beneficial Ownership Statement

Reuters
·
Jul 08

Oragenics Says All Three Australian Concussion Trial Sites Enrolling Patients

MT Newswires Live
·
Jul 07

Oragenics Says Royal Adelaide Hospital Wins Governance Approval for Phase Iia Trial Site Activation

Reuters
·
Jul 07

Oragenics Achieves Full Activation of Australian Phase Iia Trial Network — All Three Sites NOW Enrolling

THOMSON REUTERS
·
Jul 07

Oragenics Achieves Full Activation of Australian Phase IIa Trial Network — All Three Sites Now Enrolling

GlobeNewswire
·
Jul 07

Oragenics Appoints New Chief Financial Officer and Leader

TIPRANKS
·
Jul 07

Oragenics Names Senior Controller John Spencer as CFO

Reuters
·
Jul 07

Oragenics Highlights Investor Outreach at Micro-Cap Conference

TIPRANKS
·
May 19

Oragenics presents at Sidoti Micro-Cap Virtual Investor Conference

Reuters
·
May 19

Oragenics begins dosing in Australia Phase IIa ONP-002 concussion trial

Reuters
·
May 18

Oragenics Provides Investor Update

THOMSON REUTERS
·
May 18

Oragenics Q1 EPS $(0.51) Up From $(3.60) YoY

Benzinga Earnings
·
May 09

Oragenics announces annual shareholder meeting notice and proxy statement release

Reuters
·
May 09

Oragenics Q1 net loss narrows 0.71% to $2.2 million

Reuters
·
May 09

Oragenics Signs Letter of Intent to License Cardiodialysis™ Technology From Sigyn Therapeutics to Target Tbi-Induced Systemic Inflammation

THOMSON REUTERS
·
May 07

Oragenics Inc - to Pay 3% Royalty on Revenue From Sales of Licensed Technology for Six Years After FDA Clearance

THOMSON REUTERS
·
May 07